4.2 Review

Long Noncoding RNA LIFR-AS1: A New Player in Human Cancers

期刊

BIOMED RESEARCH INTERNATIONAL
卷 2022, 期 -, 页码 -

出版社

HINDAWI LTD
DOI: 10.1155/2022/1590815

关键词

-

资金

  1. Natural Science Foundation of Liaoning Province, China [2019-ZD-0772]
  2. National Natural Science Foundation of China [81471809, 81971639]

向作者/读者索取更多资源

LIFR-AS1 is a lncRNA transcribed in an antisense manner from the LIFR gene on human chromosome, and it plays a role in tumor growth, migration, invasion, apoptosis, and drug resistance through various mechanisms. It has the potential to serve as a biomarker and therapeutic target for different types of human cancers.
Emerging evidence has indicated that aberrantly expressed long noncoding RNAs (lncRNAs) play a vital role in various biological processes associated with tumorigenesis. Leukemia inhibitory factor receptor antisense RNA1 (LIFR-AS1) is a recently identified lncRNA transcribed in an antisense manner from the LIFR gene located on human chromosome 5p13.1. LIFR-AS1 regulates tumor proliferation, migration, invasion, apoptosis, and drug resistance through different mechanisms. Its expression level is related to the clinicopathological characteristics of tumors and plays a key role in tumor occurrence and development. In this review, we summarize the role of LIFR-AS1 in the development and progression of different cancers and highlight the potential for LIFR-AS1 to serve as a biomarker and therapeutic target for a variety of human cancers.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.2
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据